^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

RAS wild-type

Entrez ID:
Related biomarkers:
2d
Aberrant Glycosylation in Pancreatic Ductal Adenocarcinoma 3D Organoids Is Mediated by KRAS Mutations. (PubMed, J Oncol)
Meanwhile, mannose-binding lectin (rRSL [Ralstonia solanacearum] and rBC2LA [Burkholderia cenocepacia]) signals were higher while those of galactose-binding lectins (rGal3C and rCGL2) were lower in the KRAS mutants. We demonstrated here that PDAC 3D-cultured organoids with KRAS mutations were dominantly covered in increased fucosylated glycans, pointing towards novel treatment targets and/or tumor markers.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • FUT3 (Fucosyltransferase 3)
|
KRAS mutation • KRAS G12D • KRAS G12V • KRAS wild-type • RAS wild-type • KRAS G12 • KRAS Q61L • KRAS expression
2d
Microsatellite instability: A 2024 update. (PubMed, Cancer Sci)
Therefore, clinical relevance exists for analyses of MSI and MSI-H-associated genomic alterations in malignancy. In this article, we provide an update on MSI-driven carcinogenesis, with an emphasis on unique landscapes of diagnostic and immunotherapeutic strategies.
Review • Journal • Microsatellite instability • MSi-H Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • NTRK (Neurotrophic receptor tyrosine kinase)
|
MSI-H/dMMR • KRAS wild-type • BRAF wild-type • RAS wild-type • RAS wild-type + BRAF wild-type • NTRK fusion
5d
Critical appraisal of surgical margins according to KRAS status in liver resection for colorectal liver metastases: Should surgical strategy be influenced by tumor biology? (PubMed, Surgery)
KRAS-mutated colorectal liver metastases showed more aggressive tumor biology with inferior overall survival and disease-free survival after liver resection. Although R0 resection was not associated with improved oncologic outcomes in the KRAS-mutated tumors group, it seems to be of paramount importance for achieving prolonged long-term survival in KRAS wild-type tumors.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
7d
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer (clinicaltrials.gov)
P2, N=48, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2024 --> Feb 2025
Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
|
RAS wild-type
|
Opdivo (nivolumab) • Cabometyx (cabozantinib tablet)
7d
Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov)
P1, N=33, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Mar 2026
Trial completion date • Trial primary completion date • Combination therapy • Surgery • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
|
BRAF mutation • BRAF V600 • RAS wild-type • BRAF positive
|
Erbitux (cetuximab) • Zelboraf (vemurafenib) • irinotecan
10d
Top-Down Proteomic Assay to Evaluate KRAS4B-Compound Engagement. (PubMed, Anal Chem)
We present two applications to demonstrate the capabilities of our assay: maleimide-biotin labeling of a KRAS4BG12D cysteine mutant panel and treatment of three KRAS4B proteins (WT, G12C, and G13C) with small molecule compounds. Our results show the time- or concentration-dependence of KRAS4B-compound engagement in context of the intact protein molecule while directly mapping the compound binding site.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12D • KRAS wild-type • RAS wild-type • KRAS G12 • KRAS G13C
10d
Characterization of Ras Y4H mutants in Drosophila. (PubMed, MicroPubl Biol)
In humans, rare histidine substitution mutations at Y4 are found in HRas in cerebellar glioblastomas (cGBMs). We report here that analogous Y4H mutations in Drosophila Ras make it less sensitive to Rabex-5-mediated ubiquitination in cells and show increased frequency of vein phenotypes per wing compared to wild-type Ras, which would be consistent with Ras gain-of-function and with their appearance in human cGBMs.
Journal
|
HRAS (Harvey rat sarcoma viral oncogene homolog) • RAS (Rat Sarcoma Virus)
|
RAS mutation • RAS wild-type • HRAS mutation
10d
Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study. (PubMed, JCO Glob Oncol)
This study suggests that chemotherapy rechallenge may provide a survival benefit in the third-line treatment of mCRC. However, patient characteristics, such as sex and ECOG PS, should also be considered in treatment decisions. Further prospective studies are required to confirm our findings.
Retrospective data • Journal • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
|
Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)
11d
Effect of autologous dendritic cell cytokine-induced killer on refractory metastatic colorectal cancer: a matched case-control comparative study. (PubMed, Front Immunol)
In patients with Eastern Cooperative Oncology Group (ECOG) scale 0 or wild RAS/BRAF, DC-CIK cases showed a significant increase in OS duration compared to controls (28.03 vs. 14.53 months, p = 0.038; 18.73 vs. 11.87 months, p = 0.013, respectively). The addition of autologous DC-CIK to standard chemotherapy had a positive effect on OS of patients with refractory mCRC, especially those with liver or extra-regional lymph node metastasis, ECOG = 0, and wild RAS/BRAF status.
Journal • Metastases
|
BRAF (B-raf proto-oncogene)
|
RAS wild-type
12d
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. (PubMed, Gynecol Oncol)
Avutometinib, and to a larger extent its combination with FAK inhibitor VS-4718, demonstrated promising in vivo activity against a KRAS wild-type LGSOC-PDX. These data support the ongoing registration-directed study (RAMP201/NCT04625270).
Preclinical • Journal • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ADRB2 (Adrenoceptor Beta 2) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • PTK2B (Protein Tyrosine Kinase 2 Beta)
|
KRAS mutation • BRAF mutation • KRAS wild-type • RAS wild-type
|
avutometinib (VS-6766) • defactinib (VS-6063) • VS-4718
13d
Structural insights into non-hotspot KRAS mutations and their potential as targets for effective cancer therapies. (PubMed, J Biomol Struct Dyn)
We further test whether FDA-approved KRAS inhibitors sotorasib and adagrasib successfully inhibit the E31D and E63K mutants. Based on sharp coherence in trajectories between wild KRAS and non-hotspot mutants, it is suggested that these novel mutants do not contribute to drug resistance mechanism. Overall, we provide a comprehensive understanding of the impact of non-hotspot mutations on KRAS and their potential as targets for effective cancer therapies.Communicated by Ramaswamy H. Sarma.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12D • RAS wild-type • KRAS G12 • KRAS Q61H
|
Lumakras (sotorasib) • Krazati (adagrasib)
13d
Enrollment closed • Combination therapy • Metastases
|
RAS wild-type
|
Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • magrolimab (GS-4721)
15d
Focus on RAS Codon 61 Mutations in Metastatic Colorectal Cancer: A Retrospective Analysis. (PubMed, Cancers (Basel))
At a median follow up of 96.2 months, the median OS for codon 61 RAS-mutated patients was significantly shorter compared to RAS/BRAF wild-type (26.9 vs. 36.0 months, HR 0.56) patients, while no significant difference was observed compared to non-codon 61 RAS-mutated and BRAF V600E-mutated patients. We showed a negative prognostic impact and a statistically significant correlation between codon 61 RAS mutations and metastatic involvement of the peritoneum and ovary.
Retrospective data • Journal • Metastases
|
BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
|
BRAF V600E • BRAF V600 • BRAF wild-type • RAS mutation • RAS wild-type
16d
Sacituzumab Govitecan in Recurrent Glioblastoma (clinicaltrials.gov)
P2, N=40, Recruiting, The University of Texas Health Science Center at San Antonio | Trial primary completion date: Feb 2024 --> Aug 2024
Trial primary completion date
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
RAS wild-type • IDH wild-type
|
Trodelvy (sacituzumab govitecan-hziy)
16d
LONGBOARD: LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy (clinicaltrials.gov)
P2, N=176, Active, not recruiting, GERCOR - Multidisciplinary Oncology Cooperative Group | Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Nov 2024
Enrollment closed • Trial completion date
|
BRAF (B-raf proto-oncogene)
|
BRAF wild-type • RAS wild-type
|
Lonsurf (trifluridine/tipiracil)
16d
STRATEGIC-1: Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov)
P3, N=464, Active, not recruiting, GERCOR - Multidisciplinary Oncology Cooperative Group | Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Dec 2024 | Trial primary completion date: Jun 2021 --> Jul 2023
Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
NRAS mutation • KRAS wild-type • RAS mutation • RAS wild-type • NRAS wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation
|
Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
16d
Glutamine PET Imaging Colorectal Cancer (clinicaltrials.gov)
P1, N=6, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 6
Enrollment closed • Enrollment change
|
RAS wild-type
16d
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells. (PubMed, Br J Cancer)
AURKA inhibition holds promise as a therapeutic approach to overcome cetuximab resistance in RAS/RAF wild-type colorectal cancer, offering a potential means to counter the development of cancer stem cell phenotypes associated with cetuximab resistance.
Journal • Cancer stem
|
YAP1 (Yes associated protein 1)
|
RAS wild-type
|
Erbitux (cetuximab) • alisertib (MLN8237)
22d
CAPFOL: First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes (clinicaltrials.gov)
P2, N=150, Recruiting, West China Hospital | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2025
Trial completion date • Trial primary completion date • Metastases
|
BRAF (B-raf proto-oncogene)
|
RAS wild-type • RAS wild-type + BRAF wild-type
|
Erbitux (cetuximab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium
22d
AURELIO-05: A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer (clinicaltrials.gov)
P2, N=52, Active, not recruiting, SOTIO Biotech AG | Recruiting --> Active, not recruiting | Trial completion date: Nov 2025 --> Nov 2024 | Trial primary completion date: Nov 2025 --> Aug 2024
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
|
RAS wild-type
|
Erbitux (cetuximab) • nanrilkefusp alfa (SOT101)
22d
KCP-8602-801: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications (clinicaltrials.gov)
P1/2, N=277, Active, not recruiting, Karyopharm Therapeutics Inc | Trial completion date: Aug 2024 --> Dec 2024
Trial completion date
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
|
abiraterone acetate • Inqovi (decitabine/cedazuridine) • eltanexor (KPT-8602)
22d
ETCTN 10500: Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment (clinicaltrials.gov)
P1, N=64, Recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
Trial completion date • Trial primary completion date
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
|
RAS wild-type • EZH2 mutation • EZH2 wild-type
|
Tazverik (tazemetostat) • Beleodaq (belinostat)
22d
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) (clinicaltrials.gov)
P2, N=20, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2025 --> Apr 2026 | Trial primary completion date: Dec 2025 --> Apr 2026
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • PD-L2 (Programmed Cell Death 1 Ligand 2)
|
RAS wild-type
|
Keytruda (pembrolizumab)
23d
STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov)
P2, N=24, Recruiting, Immunovative Therapies, Ltd. | Phase classification: P2b --> P2 | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Nov 2023 --> Nov 2024
Phase classification • Trial completion date • Trial primary completion date • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
|
AlloStim (bioengineered allogeneic immune cells)
23d
A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. (PubMed, Eur J Cancer)
We evaluated the relative efficacy and safety of first-line EGFRIs plus doublet chemotherapy (FOLFIRI or FOLFOX) vs. bevacizumab plus doublet chemotherapy for patients with RAS WT left-sided mCRC, as well as in all- and right-sided tumors...Safety was available in 6 trials for all-sided tumors and 1 trial for left-sided tumors, each demonstrating typical class-specific adverse events. This most comprehensive meta-analysis indicates a benefit for first-line EGFRI plus chemotherapy over bevacizumab plus chemotherapy in patients with left-sided RAS WT mCRC.
Retrospective data • Review • Journal • Head-to-Head • Metastases
|
EGFR (Epidermal growth factor receptor)
|
RAS wild-type
|
Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
24d
Single-Nucleotide-Specific Lipidic Nanoflares for Precise and Visible Detection of KRAS Mutations via Toehold-Initiated Self-Priming DNA Polymerization. (PubMed, Anal Chem)
The limit of detection was as low as 10 amol, with the system functioning well in physiological media. In particular, this system allowed us to resolve genetic mutations in the KRAS gene in colorectal cancer, suggesting its high potential in clinical diagnosis and personalized medicine.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12D • KRAS wild-type • RAS wild-type • KRAS G12
26d
Study of DF9001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=362, Recruiting, Dragonfly Therapeutics | Trial primary completion date: Oct 2023 --> Oct 2024
Trial primary completion date • Combination therapy • Metastases
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
RET mutation • RAS wild-type
|
Opdivo (nivolumab) • DF9001
26d
Trial primary completion date • Combination therapy • Metastases
|
RAS wild-type
|
Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • magrolimab (GS-4721)
26d
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) (clinicaltrials.gov)
P2, N=14, Active, not recruiting, Diwakar Davar | Trial completion date: Sep 2027 --> Aug 2025 | Trial primary completion date: Sep 2025 --> Dec 2024
Trial completion date • Trial primary completion date • Combination therapy • Pan tumor • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RAS wild-type
|
Opdivo (nivolumab) • cyclophosphamide • pixatimod (PG545)
28d
Enrollment closed
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • RAS wild-type
|
Opdivo (nivolumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil) • Opdualag (nivolumab/relatlimab)
1m
CoRe_CC-3: FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer (clinicaltrials.gov)
P1, N=89, Recruiting, German Cancer Research Center | Not yet recruiting --> Recruiting
Enrollment open
|
BRAF (B-raf proto-oncogene)
|
MSI-H/dMMR • BRAF V600 • RAS wild-type
|
CC-3
1m
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database. (PubMed, Br J Cancer)
The benefit provided by EGFR mAbs in KRAS WT mCRC is associated with left-sided primary tumour location, younger patient age and absence of NRAS or BRAF mutations. Survival benefit is observed with fluorouracil but not capecitabine. Exploratory results support further research in KRAS mutant mCRC without liver metastases.
Retrospective data • Journal • Metastases
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS mutation + BRAF mutation
|
5-fluorouracil • capecitabine
1m
A multicenter study: predicting KRAS mutation and prognosis in colorectal cancer through a CT-based radiomics nomogram. (PubMed, Abdom Radiol (NY))
The CT-based radiomics nomogram demonstrates the capability to effectively predict KRAS mutation in CRC patients and stratify their prognosis preoperatively.
Clinical • Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS wild-type • RAS wild-type
1m
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer (clinicaltrials.gov)
P2, N=171, Recruiting, NuCana plc | Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Sep 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
|
KRAS wild-type • RAS wild-type • UGT1A1*1*1
|
Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • fosifloxuridine nafalbenamide (NUC-3373)
1m
Multidimensional screening of pancreatic cancer spheroids reveals vulnerabilities in mitotic and cell-matrix adhesion signaling that associate with metastatic progression and decreased patient survival. (PubMed, Biochem Biophys Res Commun)
Finally, multiplexed single-cell immunohistochemical analysis of a 25 patient PDAC tissue microarray revealed a relationship between decreased variance in Spearman r correlation for ITGA1 and PLK1 expression within the tumor cell compartment of PDAC in patients with advanced disease stage, and elevated expression of both ITGA1 and PLK1 in PDAC was found to be associated with decreased patient survival. Taken together, this work uncovers new therapeutic vulnerabilities in PDAC that are relevant to the progression of this stromal cell-rich malignancy and which may reveal strategies for improving patient outcomes.
Journal • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • PLK1 (Polo Like Kinase 1) • ITGA1 (Integrin Subunit Alpha 1) • ITGB1 (Integrin Subunit Beta 1)
|
KRAS mutation • KRAS wild-type • RAS wild-type
1m
Fusion genes in pancreatic tumors. (PubMed, Trends Cancer)
Although they are rare, the therapeutic and diagnostic importance of these genomic events should not be underestimated, highlighting the need for quality-ensured molecular diagnostics in the management of cancer. Herein we review the existing literature on the role of fusion genes in pancreatic tumors and their clinical potential as effective biomarkers and therapeutic targets.
Review • Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • FGFR2 (Fibroblast growth factor receptor 2) • NRG1 (Neuregulin 1) • NTRK (Neurotrophic receptor tyrosine kinase) • PRKACA (Protein Kinase CAMP-Activated Catalytic Subunit Alpha)
|
KRAS wild-type • FGFR2 fusion • ALK fusion • RAS wild-type • NRG1 fusion • BRAF fusion
1m
Elusive and Aggressive: Unraveling SMARCB1/INI1-Deficient Undifferentiated Carcinoma With Rhabdoid Features Arising From the Colon: A Case Report and Comprehensive Literature Review. (PubMed, Int J Surg Pathol)
The diagnosis of SWI/SNF-deficient undifferentiated carcinoma can be challenging. Correlation with clinical findings, in conjunction with IHC work-up and molecular analysis, is of utmost importance to arrive at the appropriate diagnosis and exclude potential mimics.
Review • Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
|
KRAS mutation • BRAF mutation • KRAS G12D • BRAF wild-type • RAS wild-type • KRAS G12 • NRAS wild-type • NRAS G12D
1m
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer (clinicaltrials.gov)
P2, N=34, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2024 --> Jan 2025
Trial completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • EGF (Epidermal growth factor)
|
KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61 • HRAS Q61
|
Mekinist (trametinib)
1m
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (clinicaltrials.gov)
P1, N=325, Active, not recruiting, Exelixis | Trial primary completion date: Nov 2023 --> Nov 2024
Trial primary completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability)
|
BRAF V600E • HR positive • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type
|
Tecentriq (atezolizumab) • Bavencio (avelumab) • zanzalintinib (XL092)
1m
Evidence for Unified Assessment Criteria of HER2 IHC in Colorectal Carcinoma (USCAP 2024)
CRCs that were HER2/Het+ were invariably ISH positive, while NGS was not as sensitive for HER2 amplification in this subgroup. Our results suggest that ISH is likely unnecessary for CRC with 3+ HER2 overexpression in 10-49% of tumor cells, and that NGS has suboptimal sensitivity for this cohort.
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • RAS wild-type
|
PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody • MI Tumor Seek™
1m
AB122 Platform Study (clinicaltrials.gov)
P1, N=715, Recruiting, Taiho Pharmaceutical Co., Ltd. | N=367 --> 715 | Trial completion date: May 2024 --> May 2026 | Trial primary completion date: May 2024 --> May 2026
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
KRAS mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation
|
Avastin (bevacizumab) • Cyramza (ramucirumab) • Lytgobi (futibatinib) • Yutuo (zimberelimab) • Lonsurf (trifluridine/tipiracil) • Jeselhy (pimitespib) • pamufetinib (TAS-115)
1m
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma (clinicaltrials.gov)
P1/2, N=18, Recruiting, Cantex Pharmaceuticals | Trial primary completion date: Dec 2023 --> Dec 2024
Trial primary completion date
|
RAS wild-type • IDH wild-type
|
temozolomide • azeliragon (TTP488)